Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier (BBB) TV Platform at Virtual R&D Day Today

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, will host a virtual R&D Day webinar today highlighting progress across the Company’s broad and diverse biotherapeutics portfolio enabled by its BBB transport vehicle (TV) platform. The webinar will begin at 1:00 p.m. Eastern Time and can be accessed here.

Click to view original post